The Vectra® 3 automated quantitative pathology imaging system accurately detects and measures weakly expressing and overlapping biomarkers within a single H&E, IHC or IF intact FFPE tissue section or TMA.
Please enter valid quantity
Please login to add favorites
NULL OR EMPTY CART
|Part Number||Unit Size|
You successfully added item(s) to your cart
The Vectra 3 automated quantitative pathology imaging system is available as a 6-slide or 200-slide configuration. Both accurately detect and measure weakly expressing and overlapping biomarkers within a single H&E, IHC or IF intact FFPE tissue section or TMA. Vectra and inForm® software analysis combine the power of multiplexed biomarker imaging and quantitative analysis within a familiar digital pathology workflow to accelerate your cancer immunology research.
Tissue sections or TMAs can be labeled with immunofluorescent (IF) or immunohistochemical (IHC) stains, or with conventional stains such as H&E and trichrome. When using IF or IHC stains, multiple proteins can be measured on a per tissue, per cell, or per cell compartment (e.g. nuclear, cytoplasmic) basis - even when signals are spectrally similar, are located in the same cellular compartment or are obscured by autofluorescence.
Vectra 3 introduces the Phenochart™ whole slide contextural viewer with annotation capability into the digital workflow, where pathologists and technicians can navigate around slides and identify areas of interest for high-resolution multispectral acquisition. The system features automated slide handling, multispectral imaging technology, and unique pattern-recognition-based image analysis enabling quantitative data acquisition for up to 200 slides within a single batch run. It accurately measures protein and biomarker expression and morphometric characteristics in intact tissue sections for translational studies.
Disclaimer: For research use only. Not for use in diagnostic procedures.
|Resource Type||File Name||File Format|
|Brochure||Phenoptics Brochure||PDF 2 MB|
|Product Note||Product Note: Vectra 3, Quickening the Pace of Understanding||PDF 6 MB|
|Product Note||Quantitative Pathology Imaging and Analysis||PDF 2 MB|
|Application Note||Detecting Phenotypical Subgroups in Breast Cancer using Multiplexed Protein Expression Analysis in Intact Tissue Sections||PDF 2 MB|
|Product Info||Let's Rid the World of Ribbons - Infographic||PDF 822 KB|
|Poster (All)||Understanding immune phenotypes and their spatial relationships to breast adenocarcinoma||PDF 1 MB|
|E-book||Download Phenoptics Research Solutions E-book||Link|
|Link||Multiparametric immune profiling in HPV– oral squamous cell cancer||Link|
|Poster||Evaluation Of Tumor Immune Infiltrate as a Determinant of Response to Neo-Adjuvant Lapatinib||Link|
|Scientific Paper||NEJM: Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma||Link|
|Scientific Paper||Esbona, Karla, et al. "COX-2 modulates mammary tumor progression in response to collagen density." Breast Cancer Research 18.1 (2016)||Link|
|Scientific Paper||Feng, Zipei, et al. "Multispectral Imaging of T and B Cells in Murine Spleen and Tumor." The Journal of Immunology 196.9 (2016): 3943-3950||Link|
|Scientific Paper||Woods, Katherine, et al. "Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma." Journal for immunotherapy of cancer 4.1 (2016)||Link|
|Scientific Paper||Huang, Fangjin, et al. "Quantitative imaging for development of companion diagnostics to drugs targeting HGF/MET." The Journal of Pathology: Clinical Research (2016)||Link|
|Scientific Paper||Ören, Bilge, et al. "Tumour stroma-derived lipocalin-2 promotes breast cancer metastasis." The Journal of Pathology (2016)||Link|
|Scientific Paper||Linch, Stefanie N., et al. "Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice." Proceedings of the National Academy of Sciences 113.3 (2016): E319-E327||Link|
|Scientific Paper||NEJM: PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma||Link|
|Scientific Paper||Novartis Genoptix Shows Multiplexed IHC Test Better Predicts Immunotherapy Response||Link|
|Scientific Paper||Mlecnik, Bernhard, et al. "The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis." Science translational medicine 8.327 (2016)||Link|
|Scientific Paper||Nghiem, Paul T., et al. "PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma." New England Journal of Medicine (2016)||Link|
|Scientific Poster||Optimization Strategy For Fluorescence Multiplex Immunohistochemistry Tissue Staining||Link|
|Scientific Poster||Automate Your Complete Cancer Research Workflow with Phenoptics™||Link|
|Story||How Your Immune System Can Fight Cancer||Link|
|Webinar||The Beginning of the End: Immunoprofiling Coming of Age||Link|
|Webinar||Using multiplexed IHC to Effectively Navigate the Hidden Clues of the Immunological Microenvironment||Link|
|Webinar||Untangling the tumor microenvironment: Illuminating the complex interactions and functions of immune cells||Link|